Skip to main content

Table 3 Adjusted mean (90% CI) values for QTcN and heart rate mean changes from baseline

From: The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study

  QTcN mean change from baseline: ΔQTcN (ms) Difference from placebo: ΔΔQTcN (ms) HR mean change from baseline: ΔHR (bpm) Difference from placebo: ΔΔHR (bpm)
Treatment n Adjusted mean (SE) Adjusted mean (SE) 90% CI (lower, upper) Adjusted mean (SE) Adjusted mean (SE) 90% CI (lower, upper)
Placebo 29 3.7 (1.0) 0.6 (0.8) (-0.7, 1.9) -0.3 (0.4) -0.9 (0.5) (-1.8, 0.0)
Empagliflozin 25 mg 28 4.3 (1.1)    -1.2 (0.5)   
Placebo 29 3.7 (0.9) -0.2 (0.7) (-1.4, 0.9) -0.3 (0.4) 0.0 (0.5) (-0.9, 0.8)
Empagliflozin 200 mg 30 3.4 (0.9)    -0.3 (0.5)   
Placebo 29 3.5 (1.1) 12.4 (1.0) (10.7, 14.1) -0.2 (0.4) 2.2 (0.6) (1.1, 3.3)
Moxifloxacin 400 mg 29 16.0 (1.2)    2.0 (0.6)   
  1. Adjusted means and upper and lower 90% confidence intervals (CI) for the mean population heart rate-corrected QT interval (QTcN) changes from baseline and for the mean heart rate (HR) changes from baseline between 1 and 4 hours after administration of 25 mg or 200 mg doses of empagliflozin or placebo and between 2–4 hours after administration of 400 mg moxifloxacin or placebo. Data from the full analysis set. SE, standard error; bpm, beats per minute.